Posts by month
March 2020
Right drug, wrong patient: here’s how we improve our targeting
When it comes to precision and personalised medicine (PPM), clinical practice in oncology takes pride in developing and administering treatments that selectively target components of tumour cells. But, PPM is…
COVID-19 and cancer, still more questions than answers
COVID-19 outbreak poses a severe threat to the health of millions of people worldwide, including cancer patients. What do we know about SARS-CoV-2 infection in this specific population? The analysis…
Dino Amadori passes away at the age of 83
Soul and courage: these are the two words italian oncologist Dino Amadori chose in the autobiography he published less than two years ago to describe what guided him alla along…
In memory of Aron Goldhirsch, challenging oncologist with a vision
Prof. Aron Goldhirsch, an outstanding representative of italian Medical Oncology, awarded and recognized internationally, passed away on February 26. Since 2019, he was Medical Consultant at the Breast Cancer Center…
How to make precision drugs that work better
Six lessons from the development of the first targeted anti-cancer therapy Tamoxifen famously started life as a failed contraceptive, developed by ICI (now Astra Zeneca), but with the fatal flaw…
More evidence-based info on off-patent oncology drugs
The American Association for Cancer Research (AACR) has offered help to the U.S. Food and Drug Administration (FDA) on its ambitious Project Renewal, that aims to evaluate accumulated scientific evidence…